Results following 12 weeks of treatment confirmed findings from a previous study in not showing a statistically significant benefit of Phenserine treatment over placebo.
Patient recruitment for these studies had been halted and the planned 26 week treatment period shortened to 12 weeks based on the previously released results of a 375-patient trial.
The company continues to evaluate the whole Phenserine program. There is an ongoing examination of the interim results from its ongoing phase IIb trial. The phase IIb trial seeks to evaluate the potential ability of Phenserine to lower the levels of beta-amyloid precursor protein in AD patients following six months of treatment. The reduction of the protein may lead to a slowing of disease progression.